The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment

The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment

Multiple myeloma (MM) is a haematological B cell malignancy characterised by clonal proliferation of plasma cells and their accumulation in the bone marrow. The aim of the present study is the evaluation of biological effects of Ibrutinib in human MM cell lines alone or in combination with different...

Full description

Bibliographic Details
Main Authors: Giorgio Santoni, Consuelo Amantini, Federica Maggi, Oliviero Marinelli, Matteo Santoni, Maria Beatrice Morelli
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Biomolecules
Subjects:
multiple myeloma
TRPML2
Ibrutinib
Ibrutinib resistance
Bortezomib
Online Access:https://www.mdpi.com/2218-273X/12/1/107

Similar Items

Similar Items